Recent 8-K filings for SILO
Highest-materiality recent filing
Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15
- License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
- Agreement includes initial and annual fees from low to mid five figures, milestone payments, and royalties on net revenues.
-
Silo Pharma announces 1-for-15 reverse stock split effective June 2, 2026
Every 15 shares of common stock combined into 1 share; par value unchanged at $0.0001.
-
Silo Pharma announces 1-for-15 reverse stock split effective June 2, 2026
1-for-15 reverse split effective 4:01 pm ET on June 2, 2026; post-split trading begins June 3 under same symbol SILO.
-
Silo Pharma acquires QwikAgents software and domains for 2.1M shares
Asset purchase agreement with Many Ads Inc. for QwikAgents web application and domain names (qwikagents.com, .ai, .co).
-
Silo Pharma authorizes $1M buyback; pays IR consultant 848k shares
Board approved stock repurchase program up to $1 million of common stock.
-
Silo Pharma receives Nasdaq extension until June 22, 2026 to regain minimum bid price compliance
Company failed to meet $1.00 minimum bid price requirement by initial Dec. 24, 2025 deadline.
-
Silo Pharma shareholders approve 1:2-1:20 reverse split and increase equity plan shares to 1.4M
Reverse split authorized at ratio from 1-for-2 to 1-for-20, board may implement before October 24, 2026.
-
Silo Pharma closes $2.5M registered direct offering of common stock and warrants
Sold 2,857,143 shares at $0.875/share; gross proceeds ~$2.5 million.
-
Silo Pharma launches crypto treasury strategy; appoints Corwin Yu to advisory board
Board established Crypto Advisory Board (up to 3 members); appointed Corwin Yu as first member.
-
Silo Pharma acquires crypto software and domain assets for 750,000 shares
Acquired software for r2crypto.com and domain names socialscan.info, coinfeel.net, r2crypto.com from MAVS Holdings LLC.
-
Silo Pharma terminates UMB license, enters evaluation license and option for CNS-homing peptides
Terminates 2021 Master License Agreement with University of Maryland, Baltimore effective June 30, 2025.
-
Silo Pharma receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Silo of non-compliance with minimum bid price rule after 30 consecutive business days below $1.00, from May 14 to June 26, 2025.
-
Silo Pharma closes $2M public offering of common stock and warrants
Offered 3,333,338 shares (or pre-funded warrants) plus Series A-1 and A-2 warrants for up to 3,333,338 shares each.
-
Silo Pharma provides pipeline update; pre-IND for SPC-15 pending FDA guidance
Lead asset SPC-15 (intranasal PTSD treatment) aims for first-in-human trials after FDA pre-IND feedback.
-
Silo Pharma receives US patent for stress-induced affective disorder prophylactics
USPTO granted Patent No. 12,239,614 for exclusively licensed Columbia University technology.
-
Silo Pharma issues shareholder letter: SPC-15 IND expected 2025, SP-26 animal studies in early 2025
IND submission for SPC-15 intranasal PTSD treatment expected in 2025; Phase 1 trial to follow upon FDA approval.
-
Silo Pharma shareholders re-elect board, ratify auditor, approve say-on-pay
All four director nominees re-elected: Weisblum (578,427 for, 72,755 withhold), Linsley, Munoz, Pavell.
-
Silo Pharma postpones 2024 annual meeting to Dec 20, 2024; new record date Nov 12
Annual meeting originally Nov 12, 2024, now rescheduled to Dec 20, 2024.
-
Silo Pharma posts investor presentation for Sep 2024 conference; notes SPC-15 pre-IND submitted
Presentation used at H.C. Wainwright 26th Annual Global Investment Conference on Sep 10, 2024.
-
Silo Pharma raises $2.1M in registered direct offering of 763,638 shares at $2.75
Gross proceeds ~$2.1M from sale of 763,638 common shares at $2.75 each.
-
Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15
License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
-
Silo Pharma amends license milestones with University of Maryland, Baltimore
Fourth Amendment replaces Schedule C diligence milestones under the Master License Agreement.
-
Silo Pharma raises $2M in registered direct offering with warrants
Sold 917,432 shares at $2.18/share and issued warrants for 917,432 shares at $2.06 exercise price.
-
Silo Pharma submits pre-IND to FDA for SPC-15 intranasal PTSD treatment
SPC-15 is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder.
-
Silo Pharma extends stock repurchase program to April 30, 2024
Board approved extension of $1.0M repurchase program until April 30, 2024.
-
Lead program SPC-15 (intranasal PTSD prophylactic) Pre-IND submission planned by end of Q2 2024.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.55 · Most common event other_material